

## CURRENT REPORT 36/2020 September 16, 2020

## First patient dosed in Europe within the Expansion Cohort of Phase I/II Clinical Study of SEL24/MEN1703

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow, Poland (formerly known as: Selvita S.A., further referred to as the "Issuer"), announces that on 15<sup>th</sup> of September 2020 it has received a notice from Menarini Ricerche SpA, which belongs to Menarini Group ("Menarini"), who is the sole sponsor of SEL24/MEN1703 clinical trial (accordingly to the license agreement concluded between Menarini and the Issuer, about which the Issuer has informed in a current report no. 4/2017), that the first patient has been treated in Europe with SEL24/MEN1703 within the Phase II DIAMOND-01 clinical trial in Acute Myeloid Leukemia (AML).

In accordance with information received from Menarini, the patient has been dosed into the expansion cohort after the completion of the dose escalation part of the trial, which results have been recently presented by Menarini at the 25th Annual Meeting of the European Hematology Association (EHA), about which the Issuer has informed in a current report no. 11/2020.

DIAMOND-01 (CLI24-001; NCT03008187) is a First-In-Human, Phase I/II dose escalation and cohort expansion trial in AML – relapsed or refractory as well previously untreated - patients unsuitable for chemotherapy. The aim of this phase is to further evaluate the single agent activity and the safety profile of SEL24/MEN1703 at the recommended dose, as determined in the dose escalation part of the study.

In accordance with information received from Menarini the expansion cohort, will be run in major oncology centers both in the US and in Europe including clinical sites in Italy, Spain and Poland.

Legal basis: art. 17 sec. 1 MAR - confidential information

## Representatives of the Issuer:

- Paweł Przewięźlikowski President of the Management Board
- Krzysztof Brzózka Vice-president of the Management Board